Overview
The most referenced blend in peptide communities. BPC-157 addresses local tissue repair — injected near the injury or taken orally for gut. TB-500 (Thymosin β4) works systemically, accelerating cell migration and angiogenesis throughout the body. Named for obvious reasons: this combination accelerates healing from injuries, surgeries, and chronic soft tissue damage. BPC-157 provides the local repair stimulus; TB-500 provides systemic mobilization.
Why These Pair Well
BPC-157 and TB-500 target the same outcome (tissue repair) through entirely different pathways. BPC-157 acts locally via GPCR agonism and VEGFR2 upregulation at the injury site. TB-500 acts systemically by binding G-actin, promoting cell migration and blood vessel formation throughout the body. The combination covers local and systemic repair simultaneously — zero mechanism overlap.
Note: Both can be mixed in the same syringe. Inject subcutaneous near injury site for BPC-157, any abdominal site for TB-500.
Protocol
BPC-157
250–500 mcg/day
Subcutaneous near injury site
TB-500
2–4 mg twice per week
Subcutaneous, any site
Cycle length
4–8 weeks
Then 4 weeks off
References
[1]Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. J Appl Physiol. 2011. DOI ↗
[2]Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Expert Opin Biol Ther. 2012. DOI ↗
[3]Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Nature. 2004. DOI ↗